Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$14.14 +1.1%	$14.46	$6.99 ▼ $17.75	$1.69B	1.87	2.29 million shs	1.98 million shs
EWTX Edgewise Therapeutics	$14.32 +0.8%	$15.43	$10.60 ▼ $38.12	$1.51B	0.36	1.18 million shs	955,353 shs
MCRB Seres Therapeutics	$7.23 -5.7%	$10.00	$6.53 ▼ $30.60	$63.13M	2.89	146,614 shs	61,808 shs
WVE Wave Life Sciences	$5.94 -0.2%	$6.86	$4.25 ▼ $16.74	$915.56M	-0.92	1.29 million shs	1.06 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	+1.14%	-2.55%	-3.22%	+6.96%	+54.37%
EWTX Edgewise Therapeutics	+0.77%	-3.70%	-3.50%	-44.00%	-16.31%
MCRB Seres Therapeutics	-5.74%	-12.26%	-28.27%	-51.81%	-60.56%
WVE Wave Life Sciences	-0.17%	-9.17%	-11.74%	-43.96%	-4.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	2.9027 of 5 stars	4.4	1.0	0.0	3.3	1.7	0.6
EWTX Edgewise Therapeutics	2.9546 of 5 stars	4.4	1.0	0.0	3.1	3.3	0.0
MCRB Seres Therapeutics	3.2217 of 5 stars	2.9	3.0	4.6	1.6	0.8	0.0
WVE Wave Life Sciences	4.4012 of 5 stars	3.5	1.0	4.8	3.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	32.96% Upside
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$40.22	180.88% Upside
MCRB Seres Therapeutics	1.80	Reduce	$73.67	918.90% Upside
WVE Wave Life Sciences	3.00	Buy	$21.17	256.34% Upside

Current Analyst Ratings Breakdown

Latest ARQT, EWTX, MCRB, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
4/29/2025	WVE Wave Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
4/21/2025	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$43.00 ➝ $43.00
4/9/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/8/2025	WVE Wave Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
4/3/2025	ARQT Arcutis Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/3/2025	ARQT Arcutis Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/3/2025	EWTX Edgewise Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $52.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$212.82M	7.92	N/A	N/A	$0.94 per share	15.04
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.53 per share	N/A
MCRB Seres Therapeutics	$126.33M	0.50	N/A	N/A	($0.35) per share	-20.66
WVE Wave Life Sciences	$104.94M	8.72	N/A	N/A	$0.40 per share	14.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$262.14M	-$1.04	N/A	N/A	N/A	-140.97%	-119.11%	-45.95%	8/13/2025 (Estimated)
EWTX Edgewise Therapeutics	-$100.16M	-$1.55	N/A	N/A	N/A	N/A	-26.83%	-25.67%	8/14/2025 (Estimated)
MCRB Seres Therapeutics	-$113.72M	-$4.60	N/A	N/A	N/A	N/A	N/A	-55.08%	8/12/2025 (Estimated)
WVE Wave Life Sciences	-$57.51M	-$0.84	N/A	N/A	N/A	-66.50%	-280.57%	-52.90%	8/14/2025 (Estimated)

Latest ARQT, EWTX, MCRB, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/8/2025	Q1 2025	WVE Wave Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million
3/4/2025	Q4 2024	WVE Wave Life Sciences	-$0.17	$0.17	+$0.34	$0.17	$25.60 million	$83.75 million
3/3/2025	Q4 2024	EWTX Edgewise Therapeutics	-$0.39	-$0.42	-$0.03	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
WVE Wave Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.67	2.46	2.38
EWTX Edgewise Therapeutics	N/A	26.35	26.35
MCRB Seres Therapeutics	N/A	1.12	1.12
WVE Wave Life Sciences	N/A	1.90	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
EWTX Edgewise Therapeutics	N/A
MCRB Seres Therapeutics	59.34%
WVE Wave Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
EWTX Edgewise Therapeutics	23.20%
MCRB Seres Therapeutics	4.70%
WVE Wave Life Sciences	29.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	105.93 million	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	71.86 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	162.03 million	Optionable
WVE Wave Life Sciences	240	154.13 million	108.14 million	Optionable

ARQT, EWTX, MCRB, and WVE Headlines

Recent News About These Companies

845,830 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Purchased by Voloridge Investment Management LLC

May 27 at 4:46 AM | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Lifted by Millennium Management LLC

May 25 at 3:47 AM | marketbeat.com

BNP Paribas Financial Markets Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 20, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives $21.17 Consensus PT from Brokerages

May 20, 2025 | americanbankingnews.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Increased by Northern Trust Corp

May 19, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Buy" by Analysts

May 19, 2025 | marketbeat.com

Polar Capital Holdings Plc Acquires New Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 18, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Bought by D. E. Shaw & Co. Inc.

May 17, 2025 | marketbeat.com

MPM Bioimpact LLC Raises Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 16, 2025 | marketbeat.com

FY2025 EPS Estimates for WVE Increased by Cantor Fitzgerald

May 16, 2025 | marketbeat.com

Maven Securities LTD Sells 680,000 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

May 15, 2025 | marketbeat.com

B. Riley Has Pessimistic Outlook of WVE FY2029 Earnings

May 14, 2025 | marketbeat.com

FY2028 Earnings Estimate for WVE Issued By Wedbush

May 14, 2025 | marketbeat.com

Is Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?

May 13, 2025 | msn.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by The Manufacturers Life Insurance Company

May 13, 2025 | marketbeat.com

Algert Global LLC Invests $527,000 in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 13, 2025 | marketbeat.com

Driehaus Capital Management LLC Raises Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 10, 2025 | marketbeat.com

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

WAVE Life Sciences Ltd (WVE) Q1 2025: Everything You Need To Know Ahead Of Earnings

May 9, 2025 | finance.yahoo.com

WAVE Life Sciences Ltd (WVE) Q1 2025 Earnings Call Highlights: Clinical Advancements and ...

May 9, 2025 | finance.yahoo.com

Voya Investment Management LLC Boosts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT, EWTX, MCRB, and WVE Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$14.14 +0.16 (+1.14%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$14.00 -0.14 (-0.99%)

As of 05/27/2025 07:47 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Edgewise Therapeutics NASDAQ:EWTX

$14.32 +0.11 (+0.77%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$14.19 -0.13 (-0.91%)

As of 05/27/2025 07:50 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Seres Therapeutics NASDAQ:MCRB

$7.23 -0.44 (-5.74%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$7.61 +0.38 (+5.26%)

As of 05/27/2025 07:23 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Wave Life Sciences NASDAQ:WVE

$5.94 -0.01 (-0.17%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$6.23 +0.29 (+4.88%)

As of 05/27/2025 07:45 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time